Trial matching for every case, before the board meets.

During prep, each case is screened against the trials the program has open. A missing criterion becomes a task before the meeting. The match is on the agenda, screening leaves the meeting with an owner and a date, and enrollment is on the record with the pathway status.

Case 44815-4 · colon adenocarcinoma · stage IIIRiverside · presented Aug 18 · screened during prepStage✓ III · on recordMSI status✓ MSI-H · on recordPerformance status✓ ECOG 1 · on recordMMR by IHCmissing from the recordordered · pathology · due +5dthe missing criterion is a task, with an ownerThe program's open trials, checked against the recordAdjuvant immunotherapy trial · stage III, MSI-H colonopen at Riverside and Anaheim · 3 of 4 criteria on recordcandidatectDNA-guided adjuvant therapy trialopen at Alhambra · 3 of 3 criteria on recordcandidateHER2-amplified colorectal trialHER2 status negative · criteria unmetexcludedflagged for board discussion · 2 candidates · on the Aug 18 agendaScreened in prep against the trials the program has open, with the one missing criterion turned into a task before the meeting.
One case, three open trials, one task.Synthetic cases. Patient details invented.

Trial candidates on the agenda and in the decision record.

The agenda row says trial candidate. The board decides the treatment and whether to screen, and the coordinator records both at the table: the screening task to the research coordinator with a due date, the consent discussion to the treating physician at the next visit.

GI tumor board · Aug 18 · agendaCase 44815-4 · colon · stage III · ready · brief attachedtrial candidate · 2 openDecision record · captured at the table, 07:58recommendation:adjuvant FOLFOX, six cycles · program colon pathway · followstrials:screen for the adjuvant immunotherapy trial · research coordinator · due +7dconsent discussion:Dr. Lin · at the Aug 22 visitif enrolled:pathway status · deviates, trial enrollment · recorded on enrollmentThe trial is an option the room sees, and screening leaves the meeting as a task with an owner and a date.

Synthetic cases and figures. Patient details invented.

Screening and enrollment tracked as tasks.

From flag to screening visit to enrollment, each step is a task on someone's list. The quarter's figures show where cases stop, and the cases that stopped are named, so the program can close the gap between matched and screened.

One quarter · four boardsevery step a task with an ownerPresented61Screened against open trials61Matched on record14Screening visit held9Enrolled4median 6 days from flag to screening visit · 3 matched cases without a screening visit, each on the research coordinator's listThe drop from matched to screened has names on it, so the program can close it.

Synthetic cases and figures. Patient details invented.

Trial access at community sites.

Most cancer patients are treated in the community, where trials are scarce. Arca's network opens trials at community sites where it can, and where it cannot, the referral to the trial site is a task with a date and a ride, and the trial visits join the patient's task list.

Community clinic · where the patient is treatedcase 44815-4 · Riverside · adjuvant therapy heretrial open on site · screening visit Aug 27Partner trial site · 24 milescase 44699-3 · trial open here onlyreferral sent · transport arranged · visit Sep 2Enrollment, on the recordpathway status · deviates, trial enrollmentthe trial visits join the task list, with datesMost patients are treated in the community. The trial comes to the site where it can, and where it cannot, the referral is a task with a date and a ride.

Synthetic cases and figures. Patient details invented.

Tell us where your oncology risk sits.

Which contracts, which sites, and who manages the follow-through today. We reply within two business days with how Arca would run alongside them, starting with one program.